ArticleBiochemistry and biophysics reports2026
Therapeutic potential of CMPP, a novel maleimide derivative, in a reserpine-induced mouse model of pain-depression dyad.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pain and depression often coexist through shared mechanisms including monoamine depletion, oxidative stress, and inflammation. Multi-target therapies remain limited. Methods: The effects of 3-Chloro-4-morpholino-1-(4-(4-(pyridin-2-yl)piperazin-1-yl)but-2-yn-1-yl)-1H-pyrrole-2,5-dione (CMPP) were assessed in a reserpine-induced mouse model of pain-depression dyad. Mice received reserpine (0.5 mg/kg, s.c., 3 days) with CMPP (5, 10, or 20 mg/kg, p.o.) or gabapentin (10 mg/kg, p.o.) for behavioral evaluation. Based on the behavioral dose-screening results, the 10 mg/kg dose of CMPP was selected for subsequent biochemical analyses. Results: Reserpine reduced paw withdrawal thresholds in von Frey and PAM tests, increased immobility in the forced swim test, and prolonged escape latency in the Morris water maze. CMPP reversed these effects. Reserpine decreased brain GSH, increased TBARS, depleted serotonin and norepinephrine, elevated glutamate, and increased MAO-A activity. CMPP increased GSH, reduced TBARS, partially restored serotonin and norepinephrine, lowered glutamate, and inhibited MAO-A. It also suppressed serum TNF-α and IL-1β. Conclusion: CMPP demonstrated antinociceptive, antidepressant-like, antioxidant, and anti-inflammatory effects, supporting its potential for treating pain-depression comorbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.